secwatch.observer — SEC 8-K summary
======================================

Issuer:     Karyopharm Therapeutics Inc. (KPTI)
CIK:        0001503802
Form:       8-K
Filed at:   2025-02-19T23:59:59+00:00
Accession:  0000950170-25-022764
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Karyopharm Q4/FY2024 rev $145M; guides FY2025 rev $140-155M; trial updates
--------------------------------------------------------------------------

- FY2024 total revenue $145.2M (flat YoY); net product revenue $112.8M (vs $112M). Q4 net product rev $29.3M (+17% YoY).
- FY2024 net loss $76.4M ($0.63 basic EPS) vs $143.1M ($1.25) prior year; cash $109.1M (Dec 2024) vs $192.4M.
- Phase 3 SENTRY myelofibrosis trial: endpoint updated to Abs-TSS; top-line data expected 2H 2025; enrollment complete 1H 2025.
- Phase 3 XPORT-EC-042 endometrial cancer trial modified: focus on pMMR/dMMR ineligible for checkpoint inhibitors; sample size 276; data mid-2026.
- FY2025 guidance: total revenue $140-155M; US XPOVIO net product rev $115-130M; R&D+SG&A $240-255M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503802/000095017025022764/0000950170-25-022764-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503802/000095017025022764/kpti-20250219.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-022764

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer